MiraDx services

For Clinicians

Miradx - KRAS-Variant Testing Services

Independent of their BRCA1/BRCA2 mutational status, who:

Miradx - ImuDx Testing Services

Patients with any type of cancer who are being considered for anti-PD1 or anti-PDL1 therapy are eligible for testing. This test predicts the risk of developing immune related adverse events in response to anti-PD1 or anti-PDL1 treatment.